Medical Oncology

, Volume 27, Issue 3, pp 571–577 | Cite as

Prospective phase II study of neoadjuvant doxorubicin followed by cisplatin/docetaxel in locally advanced breast cancer

  • Taher A. Al-TweigeriEmail author
  • Dahish S. Ajarim
  • Adher A. Alsayed
  • Mohamed M. Rahal
  • Mohamed O. Alshabanah
  • Asma M. Tulbah
  • Osama A. Al-Malik
  • Doha M. Fatani
  • Gamal A. El-Husseiny
  • Naser B. Elkum
  • Adnan A. Ezzat
Original Paper


The objective of this study is to evaluate the efficacy and safety profile of the doxorubicin followed by cisplatin/docetaxel as primary chemotherapy for patients with locally advanced breast cancer (LABC). For this evaluation, 59 patients with LABC (T2–T4, N0–N2, M0) received three cycles of doxorubicin, followed by three cycles of cisplatin/docetaxel and followed by definitive surgery and locoregional radiotherapy with or without tamoxifen. The primary end point was pathologic complete response (pCR) in breast and axilla. Fifty-nine patients were evaluable for analysis: median age: 41 years, premenopausal: 68%, median tumor size: 6.0 cm (4–10), Stage IIB: 32% and IIIA/IIIB: 68%, both ER/PR positive: 53%, Her2/neu (3+) by IHC staining: 29%. Clinical complete response was seen in 44%, and clinical partial response was seen in 56%. Breast conserving surgery was performed in 44%, and MRM in 56%. pCR in the breast was 30.5%, in axilla was 37%, and pCR in both breast and axilla was 24%. Overall at follow-up of 60 months, the disease-free (DFS) and overall survival (OS) were 70 and 82%, respectively. The DFS and OS of patients who achieved complete pathologic response in breast and axilla were 78 and 100%, respectively, while 14 patients relapsed of which 46% were Her2 positive. Sequential combination of doxorubicin followed by docetaxel/cisplatin is a safe, feasible, and active combination, which offers the possibility of conservative surgery and is associated with high clinical and pathologic response rates, with promising and encouraging survival outcomes.


Locally advanced breast cancer Neoadjuvant chemotherapy Anthracycline Cisplatin/docetaxel Pathologic complete response 



This work was supported by grant from King Faisal Specialist Hospital and Research Centre (RAC#2011-022). The authors thank the oncology data unit for their support during the preparation of this article.


  1. 1.
    Schwartsmann G. Breast cancer in South America: challenges to improve early detection and management of a public health problem. J Clin Oncol. 2001;19(Suppl 18):118S–24S.PubMedGoogle Scholar
  2. 2.
    Chopra R. The Indian scene. J Clin Oncol. 2001;19(18):106S–111S.PubMedGoogle Scholar
  3. 3.
    Adebamowo CA, Adekunie OO. Case controlled study of the epidemiological risk factors for breast cancer in Nigeria. Br J Surg. 1999;86:665–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Devi B, Tang T, Corbex M. Reduction by half the percentage of late-stage presentation for breast and cervix cancer over 4 years: a pilot study of clinical down staging in Sarawak, Malaysia. Ann Oncol. 2007;18:1172–6.CrossRefPubMedGoogle Scholar
  5. 5.
    Kaufmann M, Von Minckwitz G, Smith R, et al. International expert panel on the use of primary systemic of operable breast cancer: review and recommendations. J Clin Oncol. 2003;21:2600–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Sachelaria I, Grossbard MI, Chadha M, et al. Primary systemic therapy of breast cancer. Oncologist. 2006;11:564–89.Google Scholar
  7. 7.
    Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary and axillary lymph node response to doxorubicin based neoadjuvant chemotherapy. J Clin Oncol. 1999;17:460–9.PubMedGoogle Scholar
  8. 8.
    Therasse P, Mauriac L, Welnicka-Jaskiewicz M, et al. Final results of a randomised phase III trial comparing cyclophosphamide, epirubicin and 5 fluorouracil, with dose intensified epirubicin and cyclophosphamide plus filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTIC-NCIC-SAKK multicenter study. J Clin Oncol. 2003;21:843–50.CrossRefPubMedGoogle Scholar
  9. 9.
    Von Minckwitz G, Raab G, Caputo A, et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol. 2005;23:2676–85.CrossRefGoogle Scholar
  10. 10.
    Tafyli A, Holter J, Bova A, et al. Activity of combination chemotherapy docetaxel and epirubicin as neoadjuvant therapy for women with breast cancer. Anticancer Res. 2004;26:4911–6.Google Scholar
  11. 11.
    Steger GG, Galid A, Gnant M, et al. Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14. J Clin Oncol. 2007;25:2012–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Han S, Kim SB, Kang SS, et al. A phase II study of neoadjuvant docetaxel plus doxorubicin (KBCS-01) in stage II, III breast cancer. Breast Cancer Res Treat. 2006;98:57–61.CrossRefPubMedGoogle Scholar
  13. 13.
    Evans TR, Yellowlees A, Foster E, et al. Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an Anglo Celtic cooperative oncology group study. J Clin Oncol. 2005;23:2988–95.CrossRefPubMedGoogle Scholar
  14. 14.
    Von Minckwitz G, Blohmer JU, Raab G, et al. In vivo chemosensitivity adopted preoperative chemotherapy in patients with early stage breast cancer: the GEPARTRIO pilot study. Ann Oncol. 2005;16:56–63.CrossRefGoogle Scholar
  15. 15.
    O’Regan RM, Von Roenn JH, Carleson RW, et al. Final results of phase II trial of preoperative TAC in stage III breast cancer. Clin Breast Cancer. 2005;6:163–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Crown JP. The platinum agents: a role in breast cancer treatment. Semin Oncol. 2001;28:28–37.CrossRefPubMedGoogle Scholar
  17. 17.
    Zoli W, Flamigi A, Frassinineti GL, Bajorko P, et al. In vitro activity of taxol and taxotere in comparison with doxorubicin and cisplatin on primary cell cultures of human breast cancer. Breast Cancer Res Treat. 1995;34:63–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Belani C, Lynch T. Docetaxel in combination with platinum in patients with non small cell lung cancer: trial data and implications for clinical management. Semin Oncol. 2000;28:10–4.Google Scholar
  19. 19.
    Engblom P, Rantaen V, Kulmala J, et al. Additive and supra-additive cytotoxicity of cisplatin–taxane combinations in ovarian carcinoma cell lines. Br J Cancer. 1999;79:286–92.CrossRefPubMedGoogle Scholar
  20. 20.
    Ezzat AA, Raja MA, Berry J, et al. A phase II trial of circadian timed paclitaxel and cisplatin therapy in metastatic breast cancer. Ann Oncol. 1997;8:663–7.CrossRefPubMedGoogle Scholar
  21. 21.
    Ezzat AA, Ibrahim EM, Ajarim DS, et al. High complete pathologic response in locally advanced breast cancer using paclitaxel and cisplatin. Breast Cancer Res Treat. 2000;62:237–44.CrossRefPubMedGoogle Scholar
  22. 22.
    Ezzat AA, Ibrahim EM, Ajarim DS, et al. Phase II study of neoadjuvant paclitaxel and cisplatin for operable and locally advanced breast cancer: analysis of 126 patients. Br J Cancer. 2004;90:968–74.CrossRefPubMedGoogle Scholar
  23. 23.
    Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16.CrossRefPubMedGoogle Scholar
  24. 24.
    Mieog JS, van der Hage JA, van de Velde CJ. Neoadjuvant chemotherapy for operable breast cancer. Br J Surg. 2007;94:1189–200.CrossRefPubMedGoogle Scholar
  25. 25.
    Wolkman N, Wang J, Mamounas EP, et al. Preoperative chemotherapy in patients with operable breast cancer: nine year results from National Surgical Adjuvant Breast and Bowel project B-18. J Natl Cancer Inst Monogr. 2001;30:96–102.Google Scholar
  26. 26.
    Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy; updates of National Surgical Adjuvant Breast and Bowel project protocols B-18 and B-27. J Clin Oncol. 2008;26:778–85.CrossRefPubMedGoogle Scholar
  27. 27.
    Van der Hage JA, van de Velde CJ, Julien JP, et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of cancer trial 10902. J Clin Oncol. 2001;19:4224–37.PubMedGoogle Scholar
  28. 28.
    Bear HD, Anderson S, Smith RE, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel project protocols B-27. J Clin Oncol. 2006;24:2019–27.CrossRefPubMedGoogle Scholar
  29. 29.
    Gralow JR, Burstein HJ, Wood W, et al. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol. 2008;26:814–9.CrossRefPubMedGoogle Scholar
  30. 30.
    Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on loco-regional disease in women with operable breast cancer; findings from National Surgical Adjuvant Breast and Bowel project protocols B-18. J Clin Oncol. 1997;15:2483–93.PubMedGoogle Scholar
  31. 31.
    Smith IC, Heys SD, Hutcheon AW, et al. Neoadjuvant chemotherapy in breast cancer significantly enhanced response with docetaxel. J Clin Oncol. 2002;20:1456–66.CrossRefPubMedGoogle Scholar
  32. 32.
    Lee YJ, Doliny P, Gomez-Fernandez C, et al. Docetaxel and cisplatin as primary chemotherapy for treatment of locally advanced breast cancer. Clin Breast Cancer. 2004;5(5):371–6.CrossRefPubMedGoogle Scholar
  33. 33.
    Frasci G, D’Aiuto G, Thomas R. Weekly cisplatin, epirubicin and paclitaxel with granulocyte colony-stimulating factor support vs triweekly epirubicin and paclitaxel in locally advanced breast cancer: final analysis of a sicog phase III study. Br J Cancer. 2006;95:1005–12.CrossRefPubMedGoogle Scholar
  34. 34.
    Smith IE, A’Hern RP, Coombes GA, et al. A novel continuous infusional 5-fluorouracil based chemotherapy regimen compared with conventional chemotherapy in the neoadjuvant treatment of early breast cancer: 5 year results of the TOPIC trial. Ann Oncol. 2004;15:751–8.CrossRefPubMedGoogle Scholar
  35. 35.
    Massidda B, Atzori F, Scanu A, et al. Dose dense primary chemotherapy as part of multidisciplinary treatment for inoperable stage IIIB breast cancer, long term results of phase II trial. Oncology. 2007;72:17–26.CrossRefPubMedGoogle Scholar

Copyright information

© Humana Press Inc. 2009

Authors and Affiliations

  • Taher A. Al-Tweigeri
    • 1
    Email author
  • Dahish S. Ajarim
    • 1
  • Adher A. Alsayed
    • 1
  • Mohamed M. Rahal
    • 1
  • Mohamed O. Alshabanah
    • 2
  • Asma M. Tulbah
    • 3
  • Osama A. Al-Malik
    • 4
  • Doha M. Fatani
    • 5
  • Gamal A. El-Husseiny
    • 2
  • Naser B. Elkum
    • 6
  • Adnan A. Ezzat
    • 1
  1. 1.Department of Medical OncologyKing Faisal Specialist Hospital and Research Centre, Oncology Centre, MBC 64RiyadhKingdom of Saudi Arabia
  2. 2.Department of Radiation OncologyKing Faisal Specialist Hospital and Research CentreRiyadhKingdom of Saudi Arabia
  3. 3.Department of PathologyKing Faisal Specialist Hospital and Research CentreRiyadhKingdom of Saudi Arabia
  4. 4.Department of SurgeryKing Faisal Specialist Hospital and Research CentreRiyadhKingdom of Saudi Arabia
  5. 5.Oncology Research UnitKing Faisal Specialist Hospital and Research CentreRiyadhKingdom of Saudi Arabia
  6. 6.Department of Biostatistics and Scientific ComputingKing Faisal Specialist Hospital and Research CentreRiyadhKingdom of Saudi Arabia

Personalised recommendations